A new study is open at the Levine Cancer Institute (with many more sites to follow) adding daratumumab to Revlimid, Velcade and dexamethasone for newly diagnosed, transplant-eligible myeloma patients. The study will compare the "standard of care" with RVd vs. RVD plus daratumumab. Recently, daratumumab was FDA approved for treatment after one relapse with either Revlimid/dex or Velcade/dex based on data from the POLLUX and CASTOR clinical trials. Today, daratumumab is not FDA-approved for newly diagnosed patients. Investigators are now looking into earlier approaches because it looks to make standard myeloma treatments even better. Dr. Peter Voorhees from the Levine Cancer Institute shares more about this open study on Myeloma Crowd TV. To find this clinical trial, click here: Daratumumab with RVD Clinical Trial